Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

NCT07549698 is registered in ClinicalTrials.gov with CRISPR Therapeutics AG as lead sponsor.

NCT NCT07549698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07549698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Lead sponsor
CRISPR Therapeutics AG
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 17, 2026
Completion date
December 31, 2033
Enrollment
60 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenic purpura, itp - immune thrombocytopenia, warm autoimmune hemolytic anemia, warm autoimmune hemolytic anemia (waiha)